Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2025-04-30 Report Publication Anno…
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA: Invitation to presentation of first quarter 2025 financial results
Report Publication Announcement Classification · 98% confidence The document is an invitation announcing the upcoming release of the 'first quarter 2025 financial results' on May 8, 2025, and a subsequent presentation/webcast. It explicitly states that the 'quarterly report and presentation will be published at 07:00 CEST' and provides details for the investor presentation. Since the document itself is an announcement about the publication of a report (a quarterly report), and not the comprehensive report itself, it fits the definition of a Report Publication Announcement (RPA). The document length (2303 chars) is short, supporting the RPA classification over the full Interim Report (IR) classification.
2025-04-30 English
Photocure ASA: Invitation to presentation of first quarter 2025 financial results
Report Publication Announcement Classification · 98% confidence The document is an announcement from Photocure ASA regarding the release of its 'first quarter 2025 financial results' scheduled for May 8, 2025. It explicitly states that the 'quarterly report and presentation will be published at 07:00 CEST' and that an investor presentation will be streamed later that day. Since the document itself is an invitation/announcement about the publication of financial results and the associated presentation, and given its short length (2354 chars), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) or Earnings Release (ER) itself. It is announcing the release of those reports.
2025-04-30 English
Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making
Earnings Release Classification · 90% confidence The document is explicitly titled and structured as a 'Press Release' from Photocure ASA, dated April 29, 2025. It announces the presentation of abstracts and study protocols at the AUA 2025 conference regarding their product, Blue Light Cystoscopy (BLC®). This type of announcement, detailing recent corporate activities, scientific presentations, and clinical data updates, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is not a full financial report (10-K or IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it focuses on announcing recent business/scientific developments rather than just the release of a formal report (RPA), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede formal earnings reporting periods, or serve as major operational updates. However, given the content is purely scientific/conference-related updates and not focused on financial performance metrics (revenue, profit, EPS), it leans more towards a general corporate update. Since 'ER' is often used for quarterly/periodical financial results announcements, and this is a scientific update, I must check if a better fit exists. It is not a formal financial report (10-K, IR), nor a presentation (IP). It is a press release detailing scientific findings presented at a conference. In many databases, significant scientific/operational press releases that don't fit other specific categories often default to ER if they are timely, or RNS if they are purely regulatory/miscellaneous. Given the high level of detail about clinical data and abstracts, it functions as a major operational/scientific update. If we strictly follow the definitions, it is a press release announcing scientific progress, which is often bundled with ERs or treated as RNS. Since it is a detailed announcement of corporate activity (presenting data), ER is a strong candidate if it's near a reporting period, but RNS is the general fallback for non-standard announcements. Given the context of financial reporting databases, major operational announcements like this are frequently categorized as ER if they are timely, or RNS. I will classify it as ER as it details key operational/scientific achievements that drive future performance, which is a common component of ER packages, even if financial figures are absent in this specific text. Q2 2025
2025-04-29 English
Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press Release" from Photocure ASA, dated April 29, 2025. It announces the presentation of abstracts and trial protocols related to Blue Light Cystoscopy (BLC) at the AUA 2025 conference. This type of announcement, detailing recent corporate news, scientific findings, or conference participation, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal announcement of recent business/scientific developments rather than a comprehensive financial report (10-K, IR) or a transcript (CT), and it is not specifically about dividends, management changes, or insider trading, the most appropriate classification is Earnings Release (ER) as these press releases often accompany or summarize periodic financial/operational updates, or Regulatory Filing (RNS) as a general announcement. Given the focus on scientific data presentation at a major congress, it functions as a significant operational update, often grouped with ERs, but RNS is the safest general regulatory announcement category if ER is too specific to financial results. However, many companies issue press releases summarizing conference presentations as part of their ongoing investor relations communication, which often overlaps with ER content structure (highlights, quotes, forward-looking statements). Since it is a formal, dated announcement of corporate activity, I will classify it as an Earnings Release (ER) as these often include operational highlights, or RNS. Given the content is primarily scientific/operational updates rather than pure financial figures, RNS is a strong candidate. Let's re-evaluate the definitions. ER is 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is an announcement about conference presentations, not the financial results themselves. Therefore, RNS (General regulatory announcements and fallback category) is the best fit for a non-standard, non-financial-specific corporate announcement.
2025-04-29 English
Photocure ASA - Notice of the Annual General Meeting 5 May 2025
Remuneration Information Classification · 98% confidence The document is explicitly titled 'REPORT ON REMUNERATION TO SENIOR EXECUTIVES FOR 2024' and details the compensation structure, fixed salary, variable remuneration, and share-based compensation for the CEO, CFO, and other executives and board members for the financial year 2024. This content directly aligns with the definition of a report detailing compensation for top executives and directors. The corresponding code is DEF 14A (Remuneration Information). Although it is prepared for the AGM, its primary function is the remuneration disclosure itself, not the AGM presentation (AGM-R) or the proxy solicitation (PSI).
2025-04-11 English
Photocure ASA - Notice of the Annual General Meeting 5 May 2025
Remuneration Information Classification · 99% confidence The document is titled "GUIDELINES FOR REMUNERATION OF SENIOR EXECUTIVES AND BOARD OF DIRECTORS" and explicitly states these guidelines are for consideration at the "ANNUAL GENERAL MEETING 2025". It details the structure, principles, and types of remuneration (base salary, short-term incentives, long-term incentives/share options) for senior management. This content directly relates to the compensation structure and governance practices concerning executive pay, which falls under the scope of remuneration reports or proxy statements seeking shareholder approval. Since it details compensation policies rather than just announcing a vote result or being a general proxy statement (DEF 14A is for compensation disclosure, but this is a set of guidelines for future approval), and given the context of being presented for approval at the AGM, it strongly aligns with Remuneration Information or Governance Information. However, the specific focus on detailing compensation structure and principles, which is often a required disclosure item related to executive pay, points most directly to Remuneration Information (DEF 14A in US context, though this is Norwegian). Given the options, the detailed breakdown of compensation elements (base salary, bonus schemes, share incentive schemes) makes it a specific Remuneration Information document, which maps to the DEF 14A code in the provided schema, even if it's a pre-AGM guideline document. Revisiting the definitions: DEF 14A is 'Remuneration Information'. This document is explicitly about remuneration guidelines for executives and the board, prepared for the AGM. This is the best fit.
2025-04-11 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.